Orient Europharma Co., Ltd.
14
1
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
7.1%
1 terminated/withdrawn out of 14 trials
90.0%
+3.5% vs industry average
36%
5 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis
Role: lead
Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia
Role: collaborator
Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease
Role: lead
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Role: collaborator
Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)
Role: lead
Evaluate the Effect of Dietary Supplement on Muscle Mass and Physical Performance for Over 50 Years Old People
Role: lead
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Role: lead
2ccPA Study in Patients With Symptomatic Knee Osteoarthritis
Role: lead
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
Role: collaborator
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Role: lead
Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications
Role: collaborator
NOX-100 for Preventing Hypotension During Hemodialysis
Role: collaborator
Topical ASC-J9 Cream for Acne
Role: collaborator
NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
Role: collaborator
All 14 trials loaded